A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythematosus (SLE)
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Ianalumab (Primary) ; Iscalimab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharma KK; Novartis Pharmaceuticals
- 01 Apr 2019 Planned End Date changed from 18 Apr 2024 to 2 Aug 2023.
- 01 Apr 2019 Planned primary completion date changed from 31 Mar 2021 to 15 Apr 2021.
- 04 Feb 2019 Planned End Date changed from 25 Jan 2024 to 18 Apr 2024.